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Abstract 
G protein-coupled receptors (GPCRs) are the largest family of transmembrane signaling proteins. 
Within the gastrointestinal tract, GPCRs expressed by epithelial cells sense contents of the lumen, and 
GPCRs expressed by epithelial cells, myocytes, neurons, and immune cells participate in communication 
amongst cells. GPCRs control digestion, mediate digestive diseases, and coordinate repair and growth. 
GPCRs are the target of over one third of therapeutic drugs, including many drugs used to treat digestive 
diseases. Recent advances in structural, chemical, and cell biology research have revealed that GPCRs are 
not static binary switches that operate from the plasma membrane to control a defined set of intracellular 
signals. Rather, GPCRs are dynamic signaling proteins that adopt distinct conformations and subcellular 
distributions when associated with different ligands and intracellular effectors. An understanding of the 
dynamic nature of GPCRs has provided insights into the mechanism of activation and signaling of GPCRs, 
and has revealed opportunities for drug discovery. We review the allosteric modulation, biased agonism, 
oligomerization, and compartmentalized signaling of GPCRs that control digestion and digestive diseases. 
We highlight the implications of these concepts for the development of selective and effective drugs to treat 
diseases of the gastrointestinal tract.  
 3 
Introduction 
 G protein-coupled receptors (GPCRs) are the largest family of transmembrane signaling proteins, 
with approximately 800 members in the human genome. GPCRs transmit information about the external 
environment to the interior of the cell, and thereby control most physiological and pathological processes. 
Approximately half of GPCRs have a sensory function, and mediate olfaction, taste, perception of light, 
and pheromone signaling. Other GPCRs detect hormones, neurotransmitters, and paracrine factors, and 
mediate communication among cells. GPCRs are the target of over one third of therapeutic drugs, which 
illustrates their importance in disease and therapy 1. 
The importance, diversity, and complexity of GPCRs are illustrated by their role in digestion and 
as targets for digestive disease (Fig. 1). GPCRs with sensory functions within the digestive tract include 
receptors of taste buds for sweet, bitter, and savory tastes 2, receptors of enteroendocrine cells for amino 
acids and proteins 3, and receptors of colonocytes for luminal proteases 4. GPCRs also sense the products 
of the microbiome. For instance, secondary bile acids, which are synthesized by bacteria within the colon, 
activate Takeda GPCR 5 (TGR5) on enterochromaffin cells and enteric neurons to evoke peristalsis 5. TGR5 
expressed by cutaneous sensory nerves has been implicated in cholestatic pruritus 6, 7. GPCRs of epithelial 
cells, myocytes, enteric neurons, and immune cells participate in cell-to-cell communication in the digestive 
system. They include receptors for structurally diverse ligands, including biogenic amines (catecholamines, 
histamine, serotonin), eicosanoids, amino acid transmitters, purine nucleotides, and neuropeptides and 
peptide hormones, and proteins. Thus, GPCRs orchestrate digestion (secretion, motility, transport), control 
disease processes (diseases of motility, secretion, inflammation, pain), and regulate growth and repair. 
Drugs that activate or inhibit GPCRs are effective therapies for digestive diseases (Fig. 1). 
Although the endogenous ligands of many GPCRs are known, there remain approximately 100 
GPCRs with unidentified natural ligands. Some of these orphan GPCRs have roles in the digestive system. 
For example, the Mas-related GPCR (MRGPR) family comprises approximately 40 orphan receptors 
expressed by primary sensory neurons and mast cells 8. MrgprX2 (human) or MrgprB2 (murine homolog) 
is expressed by mast cells and mediates antibody-independent responses to basic secretagogues, including 
drugs and peptides associated with pseudo-allergic reactions 9. Substance P (SP), a gut neuropeptide, can 
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activate MrgprX2. Mast cells are in proximity to sensory nerves containing SP and calcitonin gene-related 
peptide (CGRP) in the intestine 10. Therefore, it is possible that neuropeptides and MrgprX2 mediate 
communication between sensory nerves and mast cells. Communication between sensory neurons and mast 
cells has been implicated in irritable bowel syndrome (IBS) 11. 
GPCRs share a conserved structure with seven transmembrane domains, three extracellular and 
three intracellular loops, and extracellular (N-terminal) and intracellular (C-terminal) tails of varying sizes. 
GPCRs are grouped into five families based on structural and functional similarities. The rhodopsin family 
(class A) includes receptors for neurotransmitters, peptides, visual pigments, odorants, tastants, and 
pheromones. The secretin family (class B) comprises receptors for polypeptide gut hormones, including 
glucagon, glucagon-like peptides, glucose-dependent insulinotropic polypeptide, secretin, vasoactive 
intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and growth-hormone-releasing 
hormone. The glutamate family (class C) includes metabotropic glutamate receptors, a calcium-sensing 
receptor, and gamma-aminobutyric acid (GABA) GABAB receptors. Adhesion family GPCRs possess a 
large extracellular N-terminus that is cleaved during activation. The frizzled family, which includes Frizzled 
and Smoothened proteins, are activated by lipoglycoproteins of the Wnt family (Frizzled) and Hedgehog 
family (Smoothened). All GPCR families are represented within the digestive system. 
 This review highlights how recent advances in structural, chemical, and cellular biology research 
have provided an understanding of the mechanism of action of GPCRs. The traditional view that GPCRs 
are simple on and off switches that operate at the surface of cells to control a defined set of intracellular 
signals has been superseded by the realization that GPCRs are dynamic signaling proteins that can adopt 
different conformations and subcellular distributions, depending on the mechanisms of their activation 12.  
One aspect of the dynamic nature of GPCRs was revealed using X-ray crystallography and cryo-
electron microscopy to probe GPCR structures. These approaches provided information about the 
organization of transmembrane, loop, and tail domains and their association with agonists, antagonists, G 
proteins, beta-arrestins (ARRBs), and other signaling effectors 13-17. Limitations of structural studies of 
GPCRs include a requirement to stabilize receptors and signaling complexes by mutation, fusion to 
stabilizing proteins, or with single domain antibodies (nanobodies). Moreover, structural studies only 
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provide snapshots of receptors frozen in time. However, structural analyses have revealed that GPCRs adopt 
distinct conformations when bound to different agonists, antagonists, and intracellular effector and 
regulators. Two pharmacological paradigms have emerged from an appreciation of the structural dynamism 
of GPCRs: allosteric modulation 18 and biased agonism 19. Structural studies have also provided evidence 
that certain GPCRs exist as oligomers rather than monomers 20, 21.  
A second component of the dynamic nature of GPCRs was discovered using biosensors, 
biophysical approaches and advanced imaging to study the trafficking and signaling of GPCRs in 
subcellular microdomains. These studies revealed that GPCRs are motile signaling proteins that, upon 
activation, can traffic from the cell surface to endosomes by dynamin- and clathrin-mediated endocytosis. 
GPCRs in endosomes can generate sustained signals in subcellular compartments (i.e., compartmentalized 
signaling) that control physiological and pathological processes 22-27. Thus, GPCRs in endosomes, rather 
than at the plasma membrane, might be a target for therapy 28. 
Herein we discuss allosteric modulation, biased agonism, oligomerization, and compartmentalized 
signaling of GPCRs that control digestion and digestive diseases, and consider the implications of these 
concepts for the development of drugs to treat gastrointestinal diseases. 
 
Allosteric Modulators of GPCRs: Signaling Rheostats 
The Concept of Allosteric Modulation of GPCRs 
Allosteric modulators are drugs or endogenous molecules that fine-tune the ability of agonists to 
activate GPCRs. The challenge of developing drugs that are selective for a particular GPCR subtype 
illustrates the potential of allosteric modulation for drug discovery. A single endogenous ligand can activate 
several GPCRs (e.g., acetylcholine activates five muscarinic receptors, M1-5Rs). These GPCR subtypes 
regulate processes within the digestive system and elsewhere. For example, studies in receptor knockout 
mice indicate that M1R and M3R regulate salivary secretion 29, while M2R and M3R control intestinal smooth 
muscle contraction 30. M1R, M4R, and M5R function in the central nervous system 31. Since the binding sites 
for endogenous ligands (orthosteric sites; right or proper in Greek) are conserved between GPCR subtypes, 
it is challenging to identify subtype-selective drugs that occupy the same site as the natural ligand. An 
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alternative approach to attain subtype selectivity is to develop drugs that bind to a different site (allosteric 
site; other in Greek) 32, 33. Ligands that interact with allosteric sites can induce changes in GPCR 
conformation that potentiate (positive allosteric modulators, PAMs) or inhibit (negative allosteric 
modulators, NAMs) endogenous agonists (Fig. 2). Intracellular effectors, including G proteins and ARRBs, 
are physiological allosteric modulators, since interaction with GPCRs induces changes in conformation that 
alter agonist affinity 34, 35.  
There are advantages to drugs that interact with allosteric rather than orthosteric sites. First, 
allosteric modulators might provide subtype selectivity, as the allosteric site is likely to be less conserved 
than the orthosteric site, which evolved to bind the same endogenous transmitter. Second, allosteric ligands 
modulate the activity of GPCRs that are bound to endogenous ligands, providing an opportunity to fine-
tune physiological responses. Finally, as the magnitude of an allosteric effect is limited by cooperativity 
between orthosteric and allosteric sites, allosteric ligands have a ceiling level beyond which no further 
modulation occurs, with reduced propensity for overdose and toxicity. These advantages have led to drug 
discovery efforts focused on the identification of allosteric modulators of GPCRs 18, some of which have 
progressed to clinical trials 1. However, there are only two approved allosteric modulators of GPCRs: 
maraviroc, a chemokine receptor 5 NAM that inhibits HIV entry 36, and cinacalcet, a calcium-sensing 
receptor PAM used to treat hyperparathyroidism 37. These drugs were found to be allosteric modulators 
after regulatory approval. 
The Translational and Clinical Impact of Allosteric Modulators for Digestive Diseases 
Consideration of the clinical utility of allosteric modulators of GPCRs raises two questions: are 
allosteric modulators a potential treatment for digestive diseases, and will gastrointestinal-related adverse 
events prohibit use of PAMs and NAMs for non-gastrointestinal disorders? PAMs and NAMs have been 
developed for several GPCRs found in the gastrointestinal tract; some have progressed to clinical trials 
(Table 1). 
PAMs and NAMs have been identified for M1-5R 38. Allosteric targeting of M1R, M4R, and M5R is 
an attractive treatment for disorders of the central nervous system, including schizophrenia, where subtype-
specificity would limit off-target effects on peripheral M2R and M3R, which are expressed in the digestive 
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tract 39. The M1R PAM benzyl quinolone carboxylic acid (BQCA) improves cognitive deficits but induces 
diarrhea in mice 40, 41. Compounds with differential positive cooperativity across subtypes could improve 
cognition with a lower risk of gastrointestinal side effects 42. MK-7622, a M1R PAM, sensitizes the M1R to 
acetylcholine in the nanomolar range with no effect on M2R, M3R or M4R up to 100 µM 43. MK-7622 
improved cognitive testing in preclinical models. Two phase I trials tested MK-7622. MK-7622 produced 
an increase in sigma band awake electroencephalogram, which indicated alertness. It also reversed the 
negative cognitive effects induced by scopolamine, a MR antagonist 43. Based on these results, a phase IIa 
and IIb, multicenter, randomized, double-blind, placebo-controlled, parallel group trial was undertaken to 
evaluate the efficacy and safety of MK-7622 as an adjunctive therapy to acetylcholinesterase inhibitors for 
Alzheimer's disease (ClinicalTrials.gov Identifier: NCT01852110). The trial was stopped since MK-7622 
failed to improve cognition. Diarrhea, which is acetylcholine-induced, was the most common adverse event. 
Given the prominent role of M2R and M3R in regulating gastrointestinal smooth muscle, peripherally 
restricted allosteric modulators that fine-tune the actions of acetylcholine might offer a potential therapy 
for motility and secretory disturbances and visceral pain of IBS 44. 
Opioids and associated Mu, delta, and kappa opioid receptors (MOR, DOR, KOR, respectively) 
are expressed throughout the gut. In addition to their analgesic properties, which are mediated by ORs 
expressed by primary sensory neurons and second order spinal neurons, opioids inhibit intestinal motility 
and electrolyte and fluid secretion by activating ORs on enteric neurons. Orthosteric agonists of MOR are 
used to treat pain (e.g., morphine, fentanyl) and diarrhea (e.g., loperamide). However, their usefulness is 
limited by respiratory depression, constipation and addiction. Morphine-induced analgesia is limited by 
tolerance (i.e., reduced effectiveness with sustained use). PAMs of MOR could provide effective therapy 
without adverse effects by amplifying the actions of endogenous opioids or by allowing a reduction of the 
dose of synthetic opioids. BMS-986122 is a MOR PAM that potentiates opioids and morphine 45, 46. 
However, since respiratory depression and constipation are mediated by MOR, PAMs would be expected 
to potentiate these side effects. While MOR is the prominent target of opioid analgesics, DOR also controls 
intestinal contractility 47. DOR is a target for diarrhea-predominant IBS-D 48, and enhancement of 
enkephalinergic signaling attenuates secretory diarrhea 49. BMS-986187 is a DOR PAM that amplifies the 
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actions of DOR agonists 50. By modulating endogenous opioids, DOR PAMs have the potential to inhibit 
motility without causing constipation. Despite the promise of the MOR PAM (BMS-986122) and the DOR 
PAM (BMS-986187), the therapeutic potential of these drugs is yet to be assessed and they have not been 
tested in clinical trials. 
Allosteric modulators of gut GPCRs have been described for the treatment of other digestive 
disorders. Glutamate, a transmitter of visceral and somatic pain, can activate ionotropic receptors (ion 
channels) and metabotropic GPCRs (MGLUR1-8). MGLUR5, which is expressed by vagal afferent endings 
of the gastro-esophageal sphincter, regulates sphincter tone, providing a basis for the development of 
allosteric modulators of MGLUR5 for gastro-esophageal reflux disease (GERD). ADX10059 is a 
MGLUR5 NAM. A randomized, patient-blind, placebo-controlled trial demonstrated that ADX10059 
reduced GERD-related symptoms 51. Dizziness developed in 75% of participants. ADX10059 was then 
tested, at a reduced dose, in a double-blind, placebo-controlled, multi-center trial in participants with proton 
pump inhibitor-responsive GERD. At this reduced dose, ADX10059 increased symptom- and heartburn-
free days and reduced regurgitation and sleep disturbance. Mild to moderate dizziness and vertigo were 
experienced only by 16% and 12% of patients, respectively 52 (ClinicalTrials.gov Identifier: 
NCT00820079). Testing was stopped because long term administration of ADX10059 in a trial for the 
prevention of migraine elevated hepatic transaminases (ClinicalTrials.gov Identifier: NCT00820105). Liver 
enzyme elevation resulted from metabolism of ADX10059 rather than MGLUR5 inhibition; therefore, 
negative allosteric modulation of MGLUR5 remains a viable approach for GERD. 
 
Biased-Agonism of GPCRs: Shapeshifting Receptors and Pathway-Selective Drugs 
The Concept of Biased Agonism of GPCRs 
Biased agonism describes the phenomenon whereby the binding of different ligands, including 
endogenous ligands or drugs, to the same receptor in an identical cellular background results in differential 
activation of signaling pathways 19 (Fig. 3). While this is the definition of ligand biased agonism, other 
descriptions include differential localization of activated GPCRs (location bias) or differential signaling 
between various cell types (system bias). Biased agonism provides an avenue for pathway-selective drug 
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discovery (i.e., the development of drugs that modulate the beneficial pathways rather than those that give 
rise to adverse effects). Ligand bias can be attributed to different agonists stabilizing distinct conformations 
of GPCRs that couple to particular signaling effectors. Studies of serotonin receptors bound to the ARRB-
biased agonists ergotamine and lysergic acid diethylamide support this concept 53. However, robust 
structural evidence for this mechanism of biased agonism is lacking and will require studies of GPCRs in 
multiple activation states. The realization that GPCRs can be differentially activated within intracellular 
compartments (see Compartmentalized Signaling) has sparked interest in location bias as a therapeutic 
avenue 54. Finally, system bias, which can be attributed to differences in the stoichiometric ratios of 
signaling effectors between cells, also offers a strategy for the design of effective therapies. However, these 
endeavors require an understanding of the signaling pathways in functionally relevant cells and of how they 
may be altered during disease, which, in most cases, is still lacking. Biased agonism of GPCRs has 
implications for both physiological control and drug discovery. 
The mechanisms by which serine and cysteine proteases activate protease-activated receptor-2 
(PAR2) illustrate the relevance of biased agonism of a GPCR that controls gut functions. PAR2 is expressed 
throughout the digestive system, where it regulates inflammation, pain, motility, and secretion, and is a 
therapeutic target for inflammatory and functional disorders 55. During disease, proteases become activated 
and trigger PAR2 by distinct mechanisms 56. Trypsins, from pancreatic secretions and colonocytes, and mast 
cell tryptase cleave within the extracellular N-terminus of PAR2 at the R36¯S37 to reveal a new N-terminal 
tethered ligand domain (S37LIGKV). This domain then binds to extracellular loops of cleaved PAR2, which 
couples to Gaq, Gas and ARRBs. PAR2 internalizes and can continue to signal from endosomes (see 
Compartmentalized Signaling) 25, 57. This canonical mechanism, which operates in model cell lines and 
primary sensory neurons, was once considered to be the only way proteases could activate PAR2. However, 
cathepsin-S from macrophages and neutrophil elastase cleave PAR2 at different sites from trypsin and 
tryptase and activate PAR2 by biased mechanisms 58, 59. Cathepsin-S cleaves at E56¯T57 to reveal a distinct 
tethered ligand (T57VFSVDEFSA), which binds to PAR2 and induces coupling to Gas 58. Elastase cleaves 
PAR2 at S67¯V68, close to the first transmembrane domain, and activates the receptor by a mechanism that 
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likely involves a conformational change rather than exposure of a tethered ligand, and induces PAR2 
coupling to Gas and Ga12,13 59. After cleavage by cathepsin-S and elastase, PAR2 neither couples to Gaq 
nor ARRBs and does not internalize. An understanding of these mechanisms provides insights into how 
these proteases signal PAR2-dependent pain, including inflammatory pain in the colon 25. Trypsin evokes 
hyperexcitability of primary sensory neurons by mechanisms that depend on protein kinase C (PKC) and 
extracellular signal regulated kinase (ERK), which are down-stream from Gaq 25. Cathepsin-S and elastase 
evoke hyperexcitability of neurons by adenylyl cyclase- and protein kinase A- (PKA) mediated pathways, 
downstream from Gas 25, 58, 59. The mechanisms by which proteases of different selectivity can activate 
PAR2 represents biased signaling, where the receptor couples to different G proteins depending on the site 
of cleavage. Other GPCRs that control gut functions may also be activated by biased mechanisms, although 
this has not been studied. Biased agonism is likely to be pertinent for GPCRs for neuropeptides, which 
often exist in multiple forms that might interact with receptors in different ways. 
In addition to its physiological relevance, biased agonism of GPCRs has implications for drug 
discovery. A limitation of most agonist drugs is that the same receptor mediates the beneficial and 
detrimental effects (i.e., on-target side effects). For example, MOR mediates morphine-induced analgesia, 
but also causes constipation and respiratory depression. If the signaling pathways that are responsible for 
the beneficial and detrimental actions of agonists are known, and are different, it may be possible to develop 
drugs that activate only the beneficial signaling events, thereby minimizing on-target side effects. Such 
drugs would not only be receptor-specific, but also pathway-specific, offering selectivity (Fig. 3). Although 
this concept is attractive, the development of pathway-selective biased agonists is challenging 60. The 
signaling pathways that underlie the beneficial and detrimental actions of agonists in vivo are not always 
known due to the difficulty of studying signaling in primary cells and intact animals. 
Despite these challenges, there has been interest in developing pathway-selective biased agonists 
of opioid receptors that would treat pain without on-target side effects. Interest in this area was sparked by 
the observation that mice lacking beta-arrestin2 (ARRB2) displayed altered responses to morphine 61, 62. 
ARRB2 deletion enhanced and prolonged morphine-induced analgesia, which is attributable to decreased 
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MOR desensitization. In contrast, ARRB2 deletion attenuated morphine-induced tolerance, respiratory 
depression and constipation, which suggests that ARRB2 mediates the signaling that underlies these effects 
61-63. Observations with loperamide, a peripherally-restricted MOR agonist, confirmed that ARRB2 
mediates opioid-induced constipation 64, 65. However, ARRB2 plays a role within the digestive tract, where 
it mediates the development of tolerance to morphine in the colon but not in the ileum 66-68. The observation 
that ARRB2 plays distinct roles in regulating MOR signaling that underlies analgesia versus respiratory 
suppression and constipation prompted efforts to identify biased agonists of MOR that activate G proteins 
but not ARRBs. Potentially, G protein-biased agonists would induce analgesia without on-target side 
effects. Several candidates have emerged.  
The Translational and Clinical Impact of Biased Agonists for Digestive Diseases 
TRV130 (Oliceridine, OLINVO) is a weak G protein-biased agonist of MOR 69. Consistent with 
its reduced ability to recruit ARRB2, TRV130 stimulates minimal MOR phosphorylation or internalization, 
compared to other opioids 70. TRV130 retains analgesic activity in rodents, with reduced adverse effects of 
gastrointestinal function and respiration 70. ClinicalTrials.gov lists ten trials related to TRV130 (Table 1). 
A double-blind, patient-controlled analgesia phase IIb study was designed to investigate the efficacy, safety 
and tolerability of TRV130 compared to morphine and placebo in patients with moderate to severe pain 
following abdominoplasty (ClinicalTrials.gov Identifier: NCT02335294). Although the analgesic efficacy 
of TRV130 was similar to morphine, TRV130 produced less nausea and vomiting 71. In healthy men, 
TRV130 produced greater analgesia than morphine, with a smaller reduction in respiratory function and 
less nausea and vomiting (ClinicalTrials.gov Identifier: NCT02083315) 72. These clinical trials do not report 
whether the incidence of constipation following administration of TRV130 is lower relative to morphine. 
Oliceridine was granted FDA novel drug application status in 2017, but this application was rejected due 
to safety issues and dosing concerns.  
Structure-based drug design has been used to develop G protein-biased agonists of ORs. PZM21 is 
a G protein-biased MOR agonist derived from structure-based drug design efforts facilitated by the 
resolution of the crystal structure of all opioid receptor subtypes 73. Together with PZM-21, multiple G 
protein-biased MOR agonists have been identified that provide analgesia with fewer on-target side effects 
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74. However, recent studies suggest that TRV130 and PZM21 retain their undesirable side effects with 
repeated use despite being G protein-biased 75, 76. Further studies are required to ascertain the therapeutic 
utility of G protein-biased agonists of MOR. 
Biased agonists of DOR have been tested for analgesic efficacy 77. The attractiveness of DOR 
agonists for clinical use is their reduced propensity to inhibit gastrointestinal motility and cause 
constipation, compared to MOR agonists 78, 79. The DOR agonists SNC80 and ARM390 produce 
comparable analgesia but show biased effects at the cellular and behavioral level 80. Whereas SNC80 causes 
endocytosis of DOR, ARM390 does not. Repeated injection of SNC80 produces analgesic, locomotor and 
anxiolytic tolerance, along with receptor downregulation. Repeated administration of ARM390 produces 
analgesic tolerance, but not locomotor or anxiolytic tolerance. Dorsal root ganglia from the mice treated 
with these agonists demonstrated intact DOR expression, although DOR coupling to calcium channels was 
lost. ADL5859 and ADL5747 are DOR agonists that, like ARM390, produce biased effects in preclinical 
studies 81, 82. ADL5747 and ADL5859 produce antinociception in inflammatory and neuropathic pain 
models, do not activate locomotion and do not induce DOR internalization. ADL5859 has been tested in 
clinical trials for analgesic efficacy following molar removal (ClinicalTrials.gov Identifier: 
NCT009938363), rheumatoid arthritis (ClinicalTrials.gov Identifier: NCT00626275), diabetes-induced 
peripheral neuropathy (ClinicalTrials.gov Identifier: NCT00603265), and osteoarthritis (ClinicalTrials.gov 
Identifier: NCT00979953). ADL5859 did not demonstrate analgesic efficacy in these trials. Preclinical 
testing showed ADL5747 to have higher analgesic potency than ADL5859 in a model of inflammatory pain 
in rats. However, it failed to show analgesic efficacy for osteoarthritic pain (ClinicalTrials.gov Identifier: 
NCT00979953) and postherpetic neuralgia (ClinicalTrials.gov Identifier: NCT01058642). 
 
GPCR Oligomerization: It Takes Two to Tango 
The Concept of Oligomerization of GPCRs 
Although receptor tyrosine kinases and ion channels can assemble into multimeric functional units, 
the oligomerization of GPCRs is controversial. In light of this controversy, the International Union of Basic 
and Clinical Pharmacology has developed criteria for the acceptance of GPCR oligomers 83. Criteria 
 13 
include: evidence of physical association of GPCRs in native tissues and cells, rather than in transfected 
cells; evidence of a new or different pharmacological property of the oligomer in native systems; and the 
observation of functional changes when one of the protomers is deleted in animals. Despite this controversy, 
the development of drugs that target components of a GPCR oligomer offers the possibility of selectivity 
and efficacy (Fig. 4).  
Oligomerization of Class C GPCRs 
The strongest evidence for the existence of dimers comes from the class C GPCRs (glutamate, 
GABA, calcium). Dimerization of some class C GPCRs is necessary for function, where association of two 
identical or distinct subunits forms a functional receptor. In contrast to other families, the ligand binding 
site of these GPCRs is not located within the heptahelical domain, but rather within a large extracellular 
Venus Flytrap Domain (VFT). Class C GPCR dimers are stabilized by a disulfide covalent linkage between 
the two subunits. Dimerization of these receptors is essential for allosteric coupling between the VFT and 
the heptahelical domain and thus between sites for ligand binding and G protein activation. 
Heterodimerization of the GABAB1 and GABAB2 receptors is required to mask an endoplasmic reticulum 
retention sequence, allowing translocation of receptors to the plasma membrane 84-86. Agonist binding to 
GABAB1 allosterically activates GABAB2 to initiate intracellular signal transduction. Although this 
heteromerization was first described in the brain 85, it has also been postulated to occur in the digestive tract 
87 and is supported by the colocalization of both subunits in the upper gut 88. GABAA and GABAB receptors 
are expressed throughout the gut, and can regulate relaxation of the lower esophageal sphincter, gastric and 
intestinal motility, and colonic pain 89. GABAB agonists have been proposed as a treatment for GERD but 
the incidence of centrally mediated side effects has limited therapeutic applicability 90.  
Oligomerization of Class A GPCRs 
The dimerization of class A GPCRs, although more controversial than for class C GPCRs, 
illustrates the dynamism of this receptor family, since the assembly of class A oligomers has been proposed 
to be ligand-dependent and to modulate GPCR biogenesis and endocytosis 91, 92 (Fig. 4). Dimerization of 
opioid receptors has attracted attention. Studies of purified receptors reconstituted into a phospholipid 
bilayer indicate that monomeric MOR can bind agonists and antagonists and is the minimal functional unit 
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necessary for G protein activation 93. However, structural and functional observations suggest that opioid 
receptors can dimerize. Antagonist-bound MOR crystalized as a symmetrical dimer with the interfaces 
within transmembrane helices 5 and 6 20, although these interfaces were not observed in the agonist-bound 
structure 94. MOR homodimers have been detected in both heterologous expression systems and in vivo 95.  
MOR may dimerize with DOR, since in recombinant systems a MOR-DOR heterodimer displays 
binding and functional properties that can be observed in native membranes of wild-type but not in knock-
out mice 96. However, these data have been debated. In transgenic mice expressing DOR fused to green 
fluorescent protein (DOR-GFP), there is little overlap between DOR-GFP and immunoreactive MOR in 
primary sensory and spinal neurons 97, although DOR-GFP and MOR-mCherry are coexpressed in limited 
neuronal populations 98. Within pain pathways, DOR-MOR co-expression is limited to excitatory 
interneurons and projection neurons in the dorsal horn of the spinal cord, and to neurons in parabrachial, 
amygdalar, and cortical regions of the brain 99. Within these neurons, DOR and MOR traffic and function 
independently. Despite this controversy, the MOR-DOR heterodimer has been suggested as a therapeutic 
target that could provide analgesia with decreased tolerance 100, 101. Bifunctional ligands, comprising a MOR 
agonist and a DOR antagonist, have been generated with the rationale that DOR antagonists may enhance 
MOR responses.  
Although functional coexpression of MOR and DOR by the same neuron was first demonstrated 
using electrophysiological recordings from enteric neurons 102, the definitive demonstration of MOR-DOR 
heteromers in enteric neurons is lacking. DOR-GFP is coexpressed in a subpopulation of myenteric neurons 
with immunoreactive MOR 103. However, whether they form heteromers or functionally interact through 
other mechanisms has not been determined. Electrophysiological and molecular studies show that MOR 
and DOR are coexpressed by afferent neurons innervating the mouse colon, where receptors may suppress 
neuronal excitability during inflammation 104. 
The Translational and Clinical Impact of GPCR Oligomers for Digestive Diseases 
The utility of bivalent drugs that recognize both components of a GPCR dimer is illustrated by 
finding that a molecule with MOR agonist and DOR antagonist activity (Eluxadoline) acts through the 
MOR-DOR heteromer 105 (Table 1) (Fig. 4). Eluxadoline relieves abdominal pain in patients with IBS-D 
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(ClinicalTrials.gov Identifier: NCT01553747; NCT01553591) 48, 106. Despite the MOR activity, the drug 
showed no evidence of abuse potential in phase II and III clinical studies 107. A clinical trial is open to test 
whether Eluxadoline is effective for the management of IBS-D in patients with bile acid malabsorption 
(ClinicalTrials.gov Identifier: NCT03441581). Eluxadoline will be tested for the management of diarrhea-
associated fecal incontinence (ClinicalTrials.gov Identifier: NCT03489265). 
 
Compartmentalized Signaling: Adding Texture to GPCR Responses 
The Concept of Compartmentalized Signaling of GPCRs 
While alterations in the conformation of GPCRs might account for allosteric modulation and biased 
agonism, and could explain the altered functions of GPCR oligomers, GPCRs also undergo positional 
changes during their activation-deactivation cycle, exemplified by agonist-induced endocytosis. Agonist-
induced endocytosis in vivo has been demonstrated for the NK1R and DOR, due to the availability of 
selective NK1R antibodies and transgenic mice expressing DOR-GFP. Physiological stimuli evoke NK1R 
endocytosis in endothelial cells of post-capillary venules at sites of neurogenic inflammation 108, in enteric 
neurons during inflammation 109, and in second order spinal neurons after painful stimuli 24, 110, 111. 
Exogenous and endogenously-released opioids induce endocytosis of DOR in myenteric neurons 47, 103. 
These studies led to the appreciation that GPCRs can signal from endosomes as well as the plasma 
membrane, with implications for physiological control and drug discovery 23, 26, 28. GPCRs in endosomes 
can generate sustained signals in subcellular compartments (i.e., compartmentalized signaling) that 
contribute to important pathophysiological processes, and endosomal GPCRs could be an important target 
for therapy. 
Control of Plasma Membrane Signaling of GPCRs 
Plasma membrane signaling is regulated by ligand degradation and reuptake and by receptor 
desensitization and endocytosis, and is often transient (Fig. 5). Cell surface peptidases degrade 
neuropeptides and terminate their biological effects. Neprilysin degrades and inactivates SP and bradykinin 
and attenuates their proinflammatory actions 112-114. Neprilysin deletion causes NK1R-dependent plasma 
extravasation in the digestive tract 115, and exacerbates inflammation of the intestine due to impaired 
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degradation of SP 114. Enkephalin-degrading enzymes regulate activation of opioid receptors, and inhibitors 
of these enzymes suppress diarrhea by enhancing the anti-secretory actions of endogenous opioids 49. 
GPCR desensitization also regulates signaling at the plasma membrane. ARRBs uncouple GPCRs 
from G proteins and couple GPCRs to the clathrin-mediated endocytic machinery 116. Desensitization of 
MOR and analgesic tolerance to opioids are associated with a reduction of MOR at the plasma membrane 
117. However, tolerance to morphine develops for pain and for motility of the upper gut but not the colon, 
leading to constipation with escalating doses of opioids that are required to control pain 68. Differential 
functions of ARRBs may account for these differences in tolerance. 
Intracellular Signaling of GPCRs 
Although endosomes were considered to be a conduit for receptor trafficking to recycling or 
degradatory pathways, endosomes are now considered to be a major site of continued signaling by GPCRs 
22-27, 118-121. GPCRs in endosomes can assemble signaling complexes (signalosomes) in subcellular 
compartments. The spatial and temporal characteristics of these signals can provide a mechanism 
underlying specific cellular responses (Fig. 5). 
The idea of compartmentalized signaling, while initially proposed for cAMP 122, was first 
demonstrated for calcium signaling due to the availability of fluorescent indicators that allowed 
observations of calcium sparks, puffs and blinks within living cells 123. The use of genetically encoded 
Förster Resonance Energy Transfer biosensors that are targeted to particular subcellular domains has 
revealed that most signals are compartmentalized 124. Signal compartmentalization can be achieved by the 
formation of signaling microdomains, such as those described for receptors that stimulate the formation of 
cAMP. Here, local second-messenger concentrations are controlled by the proximity of adenylyl cyclase 
(generates cAMP), phosphodiesterases (degrade cAMP) and cAMP-activated PKA 125. Scaffolding proteins 
that lack enzymatic activity but participate in the organization of signaling effectors can mediate signal 
compartmentalization. A-kinase anchoring proteins (AKAPs) are recognized for their roles in the formation 
of multi-protein complexes that modulate spatial and temporal cAMP signaling 125. ARRBs serve as 
molecular scaffolds that recruit GPCRs, including PAR2 and NK1R, and components of the mitogen-
activated protein kinase cascade to endosomes for the activation of ERK in subcellular compartments 57, 126. 
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Although most descriptions of compartmentalized GPCR signaling in physiological settings have been 
focused on the heart and brain, signal compartmentalization in the gastrointestinal tract has been reported 
for cAMP 127. 
Control of the Endosomal Signaling of GPCRs 
The trafficking of GPCRs through the endosomal system, which depends in part on the stability of 
agonist-GPCR-ARRB complexes, governs the speed of receptor recycling and resensitization and the 
duration of endosomal signals. Initially, GPCRs that exhibited sustained interactions with ARRBs were 
designated Class B GPCRs (e.g., NK1R, PAR2) 128, 129 and those that exhibited low affinity and transient 
interactions with ARRBs were termed Class A GPCRs (e.g., NK3R, MOR) 130. While this initial 
classification has been linked to the dynamics of receptor internalization and recycling, it has become 
apparent that not all GPCRs fall in these two categories. Despite this, the differential affinity for ARRBs 
can affect signaling of receptors that are coexpressed in enteric neurons, where the activated NK1R 
sequesters ARRBs and thereby inhibits ARRB-dependent desensitization and endocytosis of the NK3R 130. 
This process may provide a mechanism for sustained signaling by tachykinins through the NK3R even after 
the NK1R is desensitized and internalized. 
In the case of neuropeptide receptors, degradation of ligands by endosomal peptidases also 
determines stability of agonist-GPCR-ARRB complexes and controls GPCR trafficking and signaling. 
Endothelin-converting enzyme 1 (ECE1) is a transmembrane peptidase found in early endosomes of many 
cells, including enteric neurons and endothelial cells 131-134. By degrading SP and CGRP in acidic 
endosomes, ECE1 destabilizes the agonist-GPCR-ARRB complex, which terminates endosomal signaling 
and promotes receptor recycling and resensitization. This mechanism controls the proinflammatory and 
neurotoxic actions of SP and the NK1R 135. The susceptibility of endogenous peptides and peptidic drugs to 
degradation by endosomal ECE1 has implications for physiological control and therapy. Somatostatin 
(SST) isoforms exist with 14 or 28 amino acids. Both isoforms of SST evoke endocytosis of the 
somatostatin receptor-2 (SSTR2), which is expressed throughout the enteric nervous system. After 
activation by SST14, SSTR2 recycles, whereas after activation by SST28, SSTR2 remains in endosomes, 
from where it may continue to signal 136. This difference is attributable to differential susceptibility of the 
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SST isoforms to degradation by ECE1. ECE1 degrades SST14 in endosomes, which destabilizes the SST14-
SSTR2-ARRB complex, allowing the receptor to recycle 136, 137. Since ECE1 does not degrade SST28, 
SSTR2 remains in endosomes. Although metabolically stable SST analogs (e.g., octreotide) are effective 
treatments for several disorders 138, they have side effects in the gastrointestinal tract (constipation, cramps, 
nausea). Stable SST analogs that are resistant to ECE1 evoke prolonged sequestration of SSTR2 in enteric 
neurons, which may generate long-lasting signals that underlie beneficial and detrimental actions 136.  
Mechanisms of Endosomal GPCR Signaling 
The concept that endosomes are a major site for sustained GPCR signaling was suggested by 
observations that ARRBs serve as molecular scaffolds that recruit GPCRs and components of the mitogen-
activated protein kinase cascades to endosomes 57, 126. It is now apparent that GPCRs in endosomes can 
signal by ARRB- and G protein-mediated mechanisms, and that endosomal signaling activates kinases and 
generates cAMP in defined subcellular compartments 22-27, 118-121 (Fig. 5). How is it possible that GPCRs 
can signal from endosomes by ARRB- and G protein-mediated mechanisms, when ARRBs uncouple 
GPCRs from G proteins at the plasma membrane? Structural studies of the β2-adrenergic receptor have 
identified receptor-G protein-ARRB megaplexes and revealed that conformations of GPCR-ARRB 
complexes retain the capacity to couple to Ga subunits 139, 140. 
The Translational and Clinical Impact of GPCR Compartmentalized Signaling for Digestive Diseases 
The therapeutic relevance of endosomal GPCR signaling is now evident 28. Whereas GPCR 
signaling at the plasma membrane is transient, endosomal signaling by the same receptor can be sustained 
and regulate events in the cell, including gene transcription in the case of the β2-adrenergic receptor and 
NK1R 24, 121. Endosomal signaling by GPCRs in the pain pathway, including the SP NK1R and the CGRP 
calcitonin receptor-like receptor (CLR) in second order spinal neurons 24, 27, and PAR2 in primary spinal 
afferent neurons 25, is critical for the sustained activation and hyperexcitability of neurons that is a hallmark 
of chronic pain. Indeed, receptor endocytosis is required for these receptors to exhibit the full repertoire of 
signaling responses. Inhibitors of clathrin and dynamin, and lipid-conjugated antagonists that target NK1R, 
CLR and PAR2 in endosomes block signaling derived from endosomal receptors. Such inhibitors provide 
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relief from pain in preclinical models of somatic and colonic pain 24, 25, 27 illustrating the pathophysiological 
relevance of endosomal GPCR signaling. Endosomally-targeted antagonists of PAR2 may be effective 
treatments for IBS pain, in which colonic proteases and PAR2 are strongly implicated 25, 141, 142. 
Endosomally-targeted agonists and antagonists of GPCRs may provide options for therapy where this has 
proven to be clinically ineffective 28.  
 
Future Directions 
 GPCRs control digestion and digestive diseases, and are a target for therapy. GPCRs sense the 
contents of the lumen, mediate the actions of gut hormones, neurotransmitters and paracrine agents, and 
control inflammation and pain. Drugs that activate or inhibit these receptors have been a mainstay for the 
treatment of digestive disorders (e.g., histamine H2 receptor antagonists for peptic ulcer disease 143).  
However, we have but a superficial understanding of this large and complex family of receptors in 
digestion and digestive diseases. The functions and roles in the gut of orphan GPCRs, such as MRGPRs, 
leucine rich GPCRs, frizzled and adhesion receptors, are still unknown. The concepts of allosteric 
modulation, biased agonism, oligomerization and compartmentalized signaling offer new opportunities for 
therapy. The successful exploitation of these concepts for the development of superior therapies requires a 
complete understanding of receptor expression, signaling and trafficking in important cell types in health 
and diseased states, which is lacking. 
 Progress in structural, chemical and cell biology, and genetics will advance understanding of the 
function of GPCRs and the development of GPCR-directed therapies. Conventional drug discovery 
involves screens of libraries of millions of drug-like molecules. Although this approach has yielded success, 
some GPCRs have been found to be un-druggable. An understanding of the structural basis of GPCR 
activation and signaling, coupled with advances in molecular modeling, has enabled screening of virtual 
libraries in silico, allowing rational structure-based drug design, even for orphan GPCRs 144. Cryo-electron 
microscopy 13, 14 and proximity ligation techniques coupled to mass spectrometry and proteomics 145 have 
provided fresh insights into the formation and structure of GPCR-signaling platforms. The realization that 
GPCRs can signal in defined subcellular compartments to control pathophysiologically important 
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processes, such as pain, has led to the development of compartment-selective agonists and antagonists 28. 
Analysis of compartmentalized signaling using genetically-encoded biosensors has revealed that some 
drugs can activate GPCRs in unexpected intracellular locations. Whereas opioid peptides can activate MOR 
at the plasma membrane and then in endosomes, secondary to receptor endocytosis, morphine can also 
activate MOR in the Golgi apparatus, by virtue of its ability to penetrate membranes 54. In this context, 
developments such as organoids, which replicate the complex organization of organs in tissue culture, and 
advanced genome editing using CRISPR Cas 9 hold remarkable potential in basic and translational GPCR 
research 146. The development of Designer Receptors Exclusively Activated by Designer Drugs 
(DREADDs) and optogenetics have provided important insights into GPCR signaling pathways that 
underlie important physiological processes in vivo. DREADDs are engineered to respond to inert drugs, 
but not endogenous ligands. By using transgenic and viral-delivery approaches, it is possible to express 
DREADDS in particular cell types, and then examine the consequences of GPCR activation in defined cell 
types 147, 148. Chemo-genetic approaches have been used to control the activity of enteric glial cells to 
investigate their roles in intestinal motility 149 and secretomotor function 150.  
 Much of the focus of these new technologies has been to define the function of GPCRs in the central 
nervous system and to develop more effective GPCR-directed therapies for neurological diseases. In light 
of the undoubted importance of GPCRs in the digestive system, the application of similar technologies to 
analysis of gut function may lead to advances in understanding digestive diseases.  
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Figure Legends 
 
Figure 1. GPCRs and their ligands in digestion and digestive disease. GPCRs are expressed throughout 
the digestive tract. Expression of some functionally and clinically important GPCRs in specific cell types 
in the tongue, lower esophageal sphincter, stomach, small intestine and colon are depicted. GPCRs control 
multiple processes in the gut and are targets for common diseases (e.g., GERD, gastric ulcer disease, 
disorders of intestinal motility, colonic pain and inflammation). TxR, taste receptor; MGLURs, 
metabotropic glutamate receptor; GABABR, gamma-aminobutyric acid B receptor; HxR, histamine 
receptor; MxR, muscarinic acetylcholine receptor; EP3, prostaglandin receptor 3; SSTR, somatostatin 
receptor; 5HTxR, serotonin receptor; FFARs, free fatty acid receptors; P2YR, purinergic 2Y receptor; OR, 
opioid receptor; NKR, neurokinin receptor; PAR, protease-activated receptor; CBR, cannabinoid receptor; 
BKR, bradykinin receptor; CLR, calcitonin receptor-like receptor; RAMP1, receptor activity modifying 
protein 1; CCKAR, cholecystokinin A receptor; TGR5, Takeda G protein coupled receptor 5 bile-acid 
receptor; MRGPR, Mas-related G protein-coupled receptor; OTR, oxytocin receptor; VPR, vasopressin 
receptor. 
Figure 2. Allosteric modulation of GPCRs. The orthosteric site of a GPCR is the site where the 
endogenous ligand (brown) binds. Sites that are topographically distinct from the orthosteric site are named 
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allosteric sites. Ligands that bind to allosteric sites (red) can potentiate or depress the orthosteric ligand 
affinity and efficacy and are named positive allosteric modulators (PAMs) or negative allosteric modulators 
(NAMs), respectively. The simulated concentration response curves show the effect of increasing 
concentrations of PAMs (green lines) or NAMs (red lines) on the response to a GPCR agonist (black line).  
Figure 3. The therapeutic potential of biased agonists of GPCRs. Biased agonism describes the 
phenomenon whereby different ligands binding to the same GPCR in an identical cellular background elicit 
distinct signaling outcomes (pathway A and pathway B). Balanced agonists (ligand 1) are those that activate 
all signaling pathways to the same extent, leading to therapeutic effects but also to deleterious effects. When 
there is a distinction between the signaling pathways that drive a therapeutic response and those that mediate 
the adverse effects of a drug, biased agonists provide a novel avenue for pathway-directed therapeutics. In 
such a case, the drug would only trigger the desired response while sparing the unwanted, deleterious effects 
(ligand 2).  
Figure 4. Potential roles of GPCR dimerization. GPCRs have been shown to function both as monomers 
(1) and dimers (2). The formation of GPCR dimers can be triggered by agonist activation and change the 
specificity of G protein coupling (3). Such differences in effector coupling elicited by dimerization have 
prompted the development of bivalent drugs, which specifically target both protomers within a dimer (4). 
Dimerization can also provide an alternative mechanism of receptor trafficking, whereby ligands can 
promote the co-internalization of both receptors after the stimulation of only one protomer (5). 
Alternatively, the presence of a protomer that is resistant to agonist-promoted endocytosis, within a 
heterodimer, can inhibit the internalization of the complex.  
Figure 5. GPCR trafficking and compartmentalized signaling. The formation of GPCR-mediated 
signaling platforms provides a mechanism to sculpt specific cellular responses. (1) GPCRs at the plasma 
membrane form multiprotein complexes that participate in the regulation of a specific signaling pathway 
(pathway A). For example, AKAP (A-kinase anchor protein) interactions with GPCRs can scaffold the 
formation of complexes that regulate cAMP signaling by bringing in close proximity enzymes that degrade 
cAMP (phosphodiesterases, PDEs) and kinases that are activated by this second messenger (protein kinase 
A, PKA). (2) Upon prolonged agonist stimulation, GPCRs are phosphorylated by G protein receptor kinases 
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(GRKs). The phosphorylated receptor has higher affinity for the cytosolic protein ARRB. (3) ARRBs are 
adaptors that promote clathrin- and dynamin-mediated endocytosis of GPCRs. (4) ARRBs scaffold the 
formation of multiprotein complexes that result in a second wave of intracellular signaling (pathway B). 
Genetically encoded biosensors have revealed differences in the spatial and temporal profile of GPCR 
signaling from different subcellular locations (insets).  
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Table 1. Clinical trials of allosteric modulators, biased agonists and bivalent ligands of GPCRs for the 
treatment of disorders of the gastrointestinal tract or with side effects in the gastrointestinal tract. 
 
Drug Mechanism 
of action 
Clinical 
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Potential GI effect Outcome of 
trial 
ClinicalTrial.gov 
identifier 
Allosteric 
modulators 
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Diarrhea Trial stopped 
for futility; 
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NAM 
GERD Reduced reflux Further testing 
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elevated 
hepatic 
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NCT00820079 
Biased 
agonists 
     
TRV130 MOR 
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Pain Decreased nausea 
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measured in trials 
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